9 results on '"Thuraiaiyah, Janu"'
Search Results
2. Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies
- Author
-
Thuraiaiyah, Janu, Kokoti, Lili, Al-Karagholi, Mohammad Al-Mahdi, and Ashina, Messoud
- Published
- 2022
- Full Text
- View/download PDF
3. The chronobiology of migraine: a systematic review
- Author
-
Poulsen, Amanda Holmen, Younis, Samaira, Thuraiaiyah, Janu, and Ashina, Messoud
- Published
- 2021
- Full Text
- View/download PDF
4. Adenosine causes short-lasting vasodilation and headache but not migraine attacks in migraine patients:a randomized clinical trial
- Author
-
Thuraiaiyah, Janu, Al-Karagholi, Mohammad Al-Mahdi, Elbahi, Fatima Azzahra, Zhuang, Zixuan Alice, Ashina, Messoud, Thuraiaiyah, Janu, Al-Karagholi, Mohammad Al-Mahdi, Elbahi, Fatima Azzahra, Zhuang, Zixuan Alice, and Ashina, Messoud
- Abstract
Migraine is a common disabling disease with a complex pathophysiology. Headache is a frequent side effect after intravenous adenosine administration, although adenosine receptor antagonist, caffeine, relieves migraine headache. These observations suggest a possible involvement of adenosine signaling in headache and migraine pathophysiology. In a randomized, double-blinded, placebo-controlled, crossover study, 18 participants diagnosed with migraine without aura received 120 µg/kg per minute adenosine or placebo over 20 minutes. Headache intensity, migraine-associated symptoms, vital signs, the diameter of the superficial temporal artery (STA), blood flow velocity in the middle cerebral artery (V MCA ), and facial skin blood flow were measured at baseline and every 10 minutes until 2 hours after infusion start. The primary end point was the difference in the incidence of migraine attacks after adenosine infusion compared with placebo. Eighteen participants completed the study. We found no difference in the incidence of migraine after adenosine infusion (7 of 18, 39%) compared with placebo (3 of 18, 17%) ( P = 0.29). Fourteen participants reported headache after adenosine infusion (14 of 18, 78%) compared with placebo (6 of 18, 33%) ( P < 0.01). Adenosine increased heart rate ( P < 0.001), facial skin blood flow ( P < 0.05), and STA diameter (AUC T0-20min , P = 0.01) and decreased V MCA (AUC T0-20min , P < 0.001) compared with placebo. Adenosine induced headache accompanied by a short-lasting (<30 minutes) dilation of intracerebral and extracerebral arteries. The nonsignificant migraine induction might be because of the presence of several adenosine receptors with counteracting signaling, highlighting the need of more selective modulators to dissect the implication of adenosine in migraine.
- Published
- 2023
5. Involvement of adenosine signaling pathway in migraine pathophysiology:A systematic review of clinical studies
- Author
-
Thuraiaiyah, Janu, Kokoti, Lili, Al-Karagholi, Mohammad Al-Mahdi, Ashina, Messoud, Thuraiaiyah, Janu, Kokoti, Lili, Al-Karagholi, Mohammad Al-Mahdi, and Ashina, Messoud
- Abstract
Objective To systematically review clinical studies investigating the involvement of adenosine and its receptors in migraine pathophysiology. Background Adenosine is a purinergic signaling molecule, clinically used in cardiac imaging during stress tests. Headache is a frequent adverse event after intravenous adenosine administration. Migraine headache relief is reported after intake of adenosine receptor antagonist, caffeine. These findings suggest a possible involvement of adenosine signaling in migraine pathophysiology and its potential as a drug target. Methods A search through PubMed and EMBASE was undertaken for clinical studies investigating the role of adenosine and its receptors in migraine, published until September 2021. Results A total of 2510 studies were screened by title and abstract. Of these, seven clinical studies were included. The main findings were that adenosine infusion induced headache, and plasma adenosine levels were elevated during ictal compared to interictal periods in migraine patients. Conclusion The present systematic review emphasizes a potentially important role of adenosine signaling in migraine pathogenesis. Further randomized and placebo-controlled clinical investigations applying adenosine receptors modulators in migraine patients are needed to further understand the adenosine involvement in migraine.
- Published
- 2022
6. Involvement of adenosine signaling pathway in migraine pathophysiology:a systematic review of preclinical studies
- Author
-
Thuraiaiyah, Janu, Kokoti, Lili, Al-Karagholi, Mohammad Al-Mahdi, Ashina, Messoud, Thuraiaiyah, Janu, Kokoti, Lili, Al-Karagholi, Mohammad Al-Mahdi, and Ashina, Messoud
- Abstract
Background Adenosine is a purinergic signaling molecule with a wide range of physiological functions including anti- and pronociceptive properties. Adenosine receptors are expressed in the trigeminovascular system, and adenosine receptor antagonist, caffeine, relieves migraine headache. We performed a systematic review of the literature of preclinical data addressing the role of adenosine in migraine pathophysiology. Methods PubMed and EMBASE were searched for pre-clinical studies on the role of adenosine in migraine pathophysiology on September 5(th), 2021. Results A total of 2510 studies were screened by title and abstract. Of these, thirteen pre-clinical studies evaluating adenosine, adenosine A1, A2A and A3 receptors were included. These studies showed that adenosine signaling pathway is involved in controlling vascular tone. Furthermore, electrical stimulation of the trigeminal ganglion modulates the expression of adenosine A(1) and A(2A) receptors in the trigeminal ganglion and trigeminal nucleus caudalis implicating adenosine signaling pathway in pain transmission. Conclusion Preclinical studies showed that adenosine has a dual effect on vasodilation and trigeminal pain pathway due to different receptor activation, suggesting a possible role of adenosine in migraine pathophysiology. Studies investigating pharmacological characteristics of subtypes of adenosine receptors are needed to further elucidate their role as a potential target for migraine treatment.
- Published
- 2022
7. The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.
- Author
-
Karlsson, William Kristian, Ashina, Håkan, Cullum, Christopher Kjær, Christensen, Rune Häckert, Al-Khazali, Haidar Muhsen, Amin, Faisal Mohammad, Ashina, Messoud, Iljazi, Afrim, Thomsen, Andreas Vinther, Chaudhry, Basit Ali, Tesfay, Betel, Thuraiaiyah, Janu, Kokoti, Lili, Rasmussen, Nadja Bredo, Domínguez-Moreno, Rogelio, Do, Thien Phu, and Zhuang, Zixuan Alice
- Subjects
MIGRAINE prevention ,THERAPEUTIC use of monoclonal antibodies ,BIOMARKERS ,DRUG efficacy ,INTRAVENOUS therapy ,CLINICAL trials ,MIGRAINE ,NEUROPEPTIDES ,RESEARCH methodology ,PHLEBOTOMY ,MAGNETIC resonance imaging ,INTERVIEWING ,HEALTH outcome assessment ,MONOCLONAL antibodies ,CASE-control method ,DIARY (Literary form) ,SYMPTOMS ,DESCRIPTIVE statistics ,RESEARCH funding ,HEADACHE ,SUBCUTANEOUS infusions ,LONGITUDINAL method - Abstract
Background: Erenumab has demonstrated effectiveness for prevention of migraine attacks, but the treatment is costly, and a considerable proportion of patients do not respond to it. The Registry for Migraine study (REFORM) was initiated to discover biomarkers that can predict response to erenumab in patients with migraine. The specific objective was to investigate differences in erenumab efficacy based on clinical information, blood-based biomarkers, structural and functional magnetic resonance imaging (MRI), and response to intravenous infusion of calcitonin gene-related peptide (CGRP). In this first report of the REFORM study, we provide a comprehensive description of the study methodology, and present the baseline characteristics of the study population. Methods: The REFORM study was a single-center, prospective, longitudinal cohort study in adults with migraine who were scheduled to receive preventive treatment with erenumab as part of a separate, open-label, single-arm phase IV trial. The study included four periods: a 2-week screening period (Weeks -6 to -5), 4-week baseline period (Week -4 to Day 1), 24-week treatment period (Day 1 to Week 24), and a 24-week follow-up period without treatment (Week 25 to Week 48). Demographic and clinical characteristics were recorded using a semi-structured interview, whilst outcome data were obtained using a headache diary, patient-reported outcomes, blood sampling, brain MRI, and responsiveness to intravenous infusion of CGRP. Results: The study enrolled 751 participants, with a mean age ± SD of 43.8 ± 12.2 years, of which 88.8% (n = 667) were female. At enrollment, 64.7% (n = 486) were diagnosed with chronic migraine, and 30.2% (n = 227) had history of aura. The mean monthly migraine days (MMDs) was 14.5 ± 7.0. Concomitant preventive medications were used by 48.5% (n = 364) of the participants, and 39.9% (n = 300) had failed ≥ 4 preventive medications. Conclusion: The REFORM study enrolled a population with a high migraine burden and frequent use of concomitant medications. The baseline characteristics were representative of patients with migraine in specialized headache clinics. Future publications will report the results of the investigations presented in this article. Trial registration: The study and sub-studies were registered on ClinicalTrials.gov (NCT04592952; NCT04603976; and NCT04674020). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. The chronobiology of migraine:a systematic review
- Author
-
Poulsen, Amanda Holmen, Younis, Samaira, Thuraiaiyah, Janu, Ashina, Messoud, Poulsen, Amanda Holmen, Younis, Samaira, Thuraiaiyah, Janu, and Ashina, Messoud
- Abstract
Background: The paroxysmal nature of migraine is a hallmark of the disease. Some patients report increased attack frequency at certain seasons or towards the end of the week, while others experience diurnal variations of migraine attack onset. This systematic review investigates the chronobiology of migraine and its relation to the periodicity of attacks in existing literature to further understand the oscillating nature of migraine. Main body: PubMed and Embase were systematically searched and screened for eligible articles with outcome measures relating to a circadian, weekly or seasonal distribution of migraine attacks. We found that the majority of studies reported morning hours (6 am–12 pm) as the peak time of onset for migraine attacks. More studies reported Saturday as weekly peak day of attack. There was no clear seasonal variation of migraine due to methodological differences (primarily related to location), however four out of five studies conducted in Norway reported the same yearly peak time indicating a possible seasonal periodicity phenomenon of migraine. Conclusions: The findings of the current review suggest a possible role of chronobiologic rhythms to the periodicity of migraine attacks. Future studies are, however, still needed to provide more knowledge of the oscillating nature of migraine.
- Published
- 2021
9. Thuraiaiyah, Janu
- Author
-
Thuraiaiyah, Janu and Thuraiaiyah, Janu
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.